drugset / Trial / NCT00421018
Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK)
Completed
187 enrolled
Karolinska Institutet
Aerocrine AB · collabMeda AB · collabMerck Sharp & Dohme LLC · collabPhadia AB · collabRegion Stockholm · collabSwedish Council for Working Life and Social Research · collabThe Swedish Research Council · collabUppsala University · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine whether use of exhaled NO (nitric oxide) to regulate the anti-inflammatory treatment leads to increased asthma-related quality of life in patients with allergic asthma
Timeline
- Start
- 2006-11
- Primary completion
- 2010-04
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Montelukast | Other / unclassified | — | — |